title: Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
abstract: BACKGROUND
  Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status.
  
  
  METHODS
  We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan. The progression-free survival time on daily low dose oral cyclophosphamide treatment was 65 months without side effects. She was well during the chemotherapy and lived a normal working and social life.
  
  
  CONCLUSIONS
  We think that use of low dose of oral CTX should be investigated further as a strategy against tumour progression after standard chemotherapy in patients who are platinum resistant with poor performance status.
authors: Division of Medical Oncology, San Carlo IDI Sanità Hospital, Rome, Italy. r.samaritani@idi.it <r.samaritani@idi.it>
authors: Riccardo
authors: R
authors: Samaritani
authors: Giacomo
authors: G
authors: Corrado
authors: Enrico
authors: E
authors: Vizza
authors: Carlo
authors: C
authors: Sbiroli
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000150:complications / Q000556:secondary / Q000601:surgery; D003125:Colostomy; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000627:therapeutic use; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D019008:Drug Resistance, Neoplasm; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology; D017567:Karnofsky Performance Status; D007813:Laparotomy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010052:Ovariectomy; D017239:Paclitaxel / Q000008:administration & dosage; D010166:Palliative Care; D010534:Peritoneal Neoplasms / Q000556:secondary; D011994:Recombinant Proteins; D016879:Salvage Therapy; D019772:Topotecan / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000556:secondary; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D018906:Antineoplastic Agents, Alkylating; D011994:Recombinant Proteins; D014815:Vitamins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D019772:Topotecan; D003520:Cyclophosphamide; D016190:Carboplatin; D017239:Paclitaxel